Clinical Trial Update: Mithramycin for Lung, Esophagus, and Other Chest Cancers [Phase 2]

View source ↗

Summary

Phase 2 trial of Mithramycin for lung, esophageal, and other chest cancers was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Esophageal Cancer
• Gastrointestinal Neoplasms
• Lung Cancer
• Mesothelioma

Drugs mentioned

• Mithramycin (mithramycin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lung Cancer, Esophageal Cancer | Phase 2 | Status: TERMINATED | Results posted: 2019-12-30